How do you comply with the FDA requirements under 21 CFR Part 11 for electronic records and electronic signatures?
21 CFR Part 11: Implementing FDA-compliant electronic records and signatures.
Why is 21 CFR Part 11 one of the most common focuses of FDA inspections?
Electronic records are ubiquitous in the modern pharmaceutical industry—and so are the requirements for their integrity:
- Systems are being used without full 21 CFR Part 11 compliance: missing audit trails, inadequate access controls
- Electronic signatures do not meet Part 11 requirements: no individual association, no manifestation statement
- System validations for E-Records systems are incomplete or out of date
- The FDA frequently identifies Part 11 deficiencies during inspections—which can result in a warning letter
Are all of your GMP-critical IT systems fully validated and configured in accordance with 21 CFR Part 11?
How can medtech and IVD manufacturers become ISO 13485-compliant?
Successfully pass ISO 9001 and ISO 13485 audits.
Our 21 CFR Part 11 services.
We implement 21 CFR Part 11 compliance in a systematic and validation-ready manner.
Our services include:
Systematic review of all GMP-critical electronic systems against 21 CFR Part 11 requirements: audit trail configuration, access controls, e-signature mechanisms, system validation, and backup/recovery systems. Prioritized remediation plan.
Full validation of LIMS, ERP, EDMS, and other electronic records systems in accordance with GAMP5, including proof of 21 CFR Part 11 compliance. IQ/OQ/PQ packages, traceability matrix, and validation report.
Design and implementation of FDA-compliant electronic signature processes: individual assignment, manifestation, date/time stamping, and non-transferability. Training of employees on Part 11-compliant use.
Mock inspections using FDA inspection questions focused on Part 11. Review of all Part 11-related SOPs, validation documentation, and audit trail configurations.
Case Study.
Pharmaceutical manufacturer completes 21 CFR Part 11 remediation program ahead of FDA inspection.
Challenge.
- A medium-sized pharmaceutical manufacturer with FDA-regulated production discovered shortly before a routine inspection that several LIMS and ERP systems were not maintaining complete audit trails and that e-signatures were not configured in compliance with Part 11.
Measures.
- 21 CFR Part 11 Gap Analysis of All Critical Systems
- Prioritized remediation plan for 6 systems in 8 weeks
- System configuration, validation, and SOP updates
- Mock inspection with a focus on Part 11 ahead of the FDA meeting
Results.
- FDA inspection completed with no Part 11 findings
- All critical systems are fully Part 11-compliant
- Audit trail completeness increased to 100%
Why Entourage Will Make Your 21 CFR Part 11 Project a Success.
Three areas where pharmaceutical companies often fall short during Part 11 remediation efforts:
- Structure: Clear system prioritization, comprehensive validation documentation, and a complete audit trail configuration reliably close inspection gaps.
- Speed: Targeted remediation projects based on a proven model reduce the workload and ensure rapid compliance with FDA inspection requirements.
- Sustainability: Trained staff and well-maintained SOPs ensure long-term compliance with 21 CFR Part 11 even after the project is completed.
This not only ensures compliance with inspection requirements—but also creates an e-records system that consistently meets FDA requirements.
Frequently Asked Questions About 21 CFR Part 11.
21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures in regulated organizations. It defines requirements for: audit trails, access controls, system validation, e-signature binding, backup and recovery, and system security.
For all electronic systems that generate, process, or store GMP-relevant records, when used as an alternative to paper records and subject to FDA inspections. This includes LIMS, ERP, MES, eTMF, chromatography systems, and EDMS.
Closed systems are systems that can only be accessed by authorized employees of the regulated company. Open systems allow access by external parties and require additional security measures such as encryption and digital signatures.
Both regulate electronic records in GMP environments. EU Annex 11 applies to GMP-regulated systems in the EU, while 21 CFR Part 11 applies to FDA-regulated companies. In terms of content, they are largely compatible—systems that meet both requirements are usually compliant with both.
Additional services related to FDA compliance and data integrity.
Services tailored to your 21 CFR Part 11 project.
contact form
Direct and straightforward: